Gastroenterology - Chiropractic Doctor



Show All Course Information
Gastroenterology 209 : Hydrogen Sulfide SIBO
1.0

Joshua Goldenberg, ND

$20.00 USD

AudioVisual Course


More Course Information ▶
  • Recall the most common symptoms which H2S patients present with 
  • Identify which H2S treatment interventions led to a statistically significant rate of adequate patient response 
  • Evaluate an H2S SIBO case with a focus on severity and treatment history 
  • Determine reasonable treatment options for an H2S SIBO case

Approved States/Territories
  • AKAlaska
  • BCBritish Columbia
  • COColorado
  • CTConnecticut
  • DEDelaware
  • DCDistrict of Columbia
  • FLFlorida
  • GAGeorgia
  • GUGuam
  • IDIdaho
  • ILIllinois
  • INIndiana
  • IAIowa
  • KSKansas
  • MEMaine
  • MBManitoba
  • MDMaryland
  • MAMassachusetts
  • MIMichigan
  • MNMinnesota
  • MOMissouri
  • MTMontana
  • NENebraska
  • NBNew Brunswick
  • NHNew Hampshire
  • NJNew Jersey
  • NYNew York
  • NCNorth Carolina
  • NDNorth Dakota
  • NSNova Scotia
  • OHOhio
  • ONOntario
  • OROregon
  • PRPuerto Rico
  • RIRhode Island
  • SCSouth Carolina
  • SDSouth Dakota
  • TNTennessee
  • UTUtah
  • VTVermont
  • VIVirgin Islands
  • VAVirginia
  • WAWashington
  • WVWest Virginia
  • WYWyoming
  • YTYukon

Gastroenterology 208 : Handheld Device for SIBO
2.0

Joshua Goldenberg, ND

$40.00 USD

AudioVisual Course


More Course Information ▶

Hour 1

  • Distinguish what gases are measured with Aire versus Aire2
  • Judge the diagnostic agreement between Quintron and Aire devices in patients suspected of having SIBO
  • Map the relationship between ‘fermentation scores’ and ppm
  • Illustrate how you could use the Aire device to conduct formal SIBO breath tests

Hour 2

  • Extrapolate hydrogen levels in the background of high methane
  • Compare and contrast the pros and cons of using the Aire device
  • Implement the clinician dashboard for breath testing
  • Clarify why CO2 levels are not needed for Aire

Approved States/Territories
  • AKAlaska
  • BCBritish Columbia
  • COColorado
  • CTConnecticut
  • DEDelaware
  • DCDistrict of Columbia
  • FLFlorida
  • GAGeorgia
  • GUGuam
  • IDIdaho
  • ILIllinois
  • INIndiana
  • IAIowa
  • KSKansas
  • MEMaine
  • MBManitoba
  • MDMaryland
  • MAMassachusetts
  • MIMichigan
  • MNMinnesota
  • MOMissouri
  • MTMontana
  • NENebraska
  • NBNew Brunswick
  • NHNew Hampshire
  • NJNew Jersey
  • NYNew York
  • NCNorth Carolina
  • NDNorth Dakota
  • NSNova Scotia
  • OHOhio
  • ONOntario
  • OROregon
  • PRPuerto Rico
  • RIRhode Island
  • SCSouth Carolina
  • SDSouth Dakota
  • TNTennessee
  • UTUtah
  • VTVermont
  • VIVirgin Islands
  • VAVirginia
  • WAWashington
  • WVWest Virginia
  • WYWyoming
  • YTYukon

Gastroenterology 207 : Proton Pump Inhibitors for Barret's Esophagus
1.0

Joshua Goldenberg, ND

$20.00 USD

AudioVisual Course


More Course Information ▶
  • Recall the pathophysiology of the progression of Barrett’s esophagus to adenocarcinoma
  • Implement the 2022 ACG guidelines on the use of PPIs for Barrett’s esophagus
  • Evaluate the conclusions from the three competing meta-analyses on PPIs for Barrett’s
  • Apply relative risk reduction calculations to the determination of the benefit of PPIs for Barrett’s

Approved States/Territories
  • AKAlaska
  • BCBritish Columbia
  • COColorado
  • CTConnecticut
  • DEDelaware
  • DCDistrict of Columbia
  • FLFlorida
  • GAGeorgia
  • GUGuam
  • IDIdaho
  • ILIllinois
  • INIndiana
  • IAIowa
  • KSKansas
  • MEMaine
  • MBManitoba
  • MDMaryland
  • MAMassachusetts
  • MIMichigan
  • MNMinnesota
  • MOMissouri
  • MTMontana
  • NENebraska
  • NBNew Brunswick
  • NHNew Hampshire
  • NJNew Jersey
  • NYNew York
  • NCNorth Carolina
  • NDNorth Dakota
  • NSNova Scotia
  • OHOhio
  • ONOntario
  • OROregon
  • PRPuerto Rico
  • RIRhode Island
  • SCSouth Carolina
  • SDSouth Dakota
  • TNTennessee
  • UTUtah
  • VTVermont
  • VIVirgin Islands
  • VAVirginia
  • WAWashington
  • WVWest Virginia
  • WYWyoming
  • YTYukon

Gastroenterology 206
1.0

Joshua Goldenberg, ND

$20.00 USD

AudioVisual Course


More Course Information ▶
  • Describe the role of GRADE in Guideline development
  • Recall the recommendations of the ACG SIBO Guidelines
  • Identify key concepts of SIBO as delineated by the authors
  • Appraise the ACG Guidelines

Approved States/Territories
  • AKAlaska
  • BCBritish Columbia
  • COColorado
  • CTConnecticut
  • DEDelaware
  • DCDistrict of Columbia
  • FLFlorida
  • GUGuam
  • IDIdaho
  • ILIllinois
  • INIndiana
  • IAIowa
  • KSKansas
  • MEMaine
  • MBManitoba
  • MDMaryland
  • MAMassachusetts
  • MIMichigan
  • MNMinnesota
  • MOMissouri
  • MTMontana
  • NENebraska
  • NBNew Brunswick
  • NHNew Hampshire
  • NJNew Jersey
  • NCNorth Carolina
  • NDNorth Dakota
  • NSNova Scotia
  • OHOhio
  • ONOntario
  • OROregon
  • PRPuerto Rico
  • RIRhode Island
  • SCSouth Carolina
  • SDSouth Dakota
  • TNTennessee
  • UTUtah
  • VTVermont
  • VIVirgin Islands
  • VAVirginia
  • WAWashington
  • WVWest Virginia
  • WYWyoming
  • YTYukon

Gastroenterology 205 : IBS/SIBO Research
2.0

Joshua Goldenberg, ND

$40.00 USD

AudioVisual Course


More Course Information ▶
  • Implement the 2020 ACG Guidelines as it relates to breath testing for patients with IBS.
  • Implement the 2020 ACG Guidelines as it relates to breath testing for patients taking PPIs.
  • Discriminate between normal and abnormal ppm of H2S on a breath test.
  • Contrast between the microbial diversity of the small intestine in those with and without SIBO.
  • Identify the aberrant organism most associated with SIBO in the REIMAGINE study.
  • Implement the 2020 ACG Guidelines as it relates to testing IBS patients for food sensitivities.
  • Implement the 2020 ACG Guidelines as it relates to the use of low FODMAP diets in IBS patients.
  • Select the Gut Directed Hypnotherapy regimen associated with the largest effect size.
  • Explain the need for GRADE within the context of Guideline development.
  • Critique a guideline using the AGREE-II criteria.
  • Define the concepts of pre- and post-test probability.
  • Calculate a post-test probability.

Approved States/Territories
  • AKAlaska
  • BCBritish Columbia
  • COColorado
  • CTConnecticut
  • DEDelaware
  • DCDistrict of Columbia
  • FLFlorida
  • GAGeorgia
  • GUGuam
  • IDIdaho
  • ILIllinois
  • INIndiana
  • IAIowa
  • KSKansas
  • MEMaine
  • MBManitoba
  • MDMaryland
  • MAMassachusetts
  • MIMichigan
  • MNMinnesota
  • MOMissouri
  • MTMontana
  • NENebraska
  • NBNew Brunswick
  • NHNew Hampshire
  • NJNew Jersey
  • NYNew York
  • NCNorth Carolina
  • NDNorth Dakota
  • NSNova Scotia
  • OHOhio
  • ONOntario
  • OROregon
  • PRPuerto Rico
  • RIRhode Island
  • SCSouth Carolina
  • SDSouth Dakota
  • TNTennessee
  • UTUtah
  • VTVermont
  • VIVirgin Islands
  • VAVirginia
  • WAWashington
  • WVWest Virginia
  • WYWyoming
  • YTYukon

Gastroenterology 204 : Small Intestinal Bacterial Overgrowth
2.0

Joshua Goldenberg, ND

$40.00 USD

AudioVisual Course


More Course Information ▶
Hour 1
  • Define Small Intestinal Bacterial Overgrowth (SIBO) 
  • List common causes/ associations/risk factors of SIBO
  • Recall the various estimates of SIBO prevalence
  • Explain why SIBO prevalence estimates vary
  • Describe the trajectory of SIBO research over the past decades
Hour 2
  • Explain the limitations of using breath tests for the diagnosis of SIBO compared to other alternatives.
  • Describe the specific issues with glucose-based breath tests for SIBO diagnosis.
  • Describe the specific issues with lactulose-based breath tests for SIBO diagnosis.
  • Critique the North American consensus document on breath testing for SIBO

Approved States/Territories
  • AKAlaska
  • BCBritish Columbia
  • COColorado
  • CTConnecticut
  • DEDelaware
  • DCDistrict of Columbia
  • FLFlorida
  • GUGuam
  • IDIdaho
  • ILIllinois
  • INIndiana
  • IAIowa
  • KSKansas
  • MEMaine
  • MBManitoba
  • MDMaryland
  • MAMassachusetts
  • MIMichigan
  • MNMinnesota
  • MOMissouri
  • MTMontana
  • NENebraska
  • NBNew Brunswick
  • NHNew Hampshire
  • NJNew Jersey
  • NCNorth Carolina
  • NDNorth Dakota
  • NSNova Scotia
  • OHOhio
  • ONOntario
  • OROregon
  • PRPuerto Rico
  • RIRhode Island
  • SCSouth Carolina
  • SDSouth Dakota
  • TNTennessee
  • UTUtah
  • VTVermont
  • VIVirgin Islands
  • VAVirginia
  • WAWashington
  • WVWest Virginia
  • WYWyoming
  • YTYukon

Gastroenterology 203 : The Leaky Gut
1.0

Joshua Goldenberg, ND

$20.00 USD

AudioVisual Course


More Course Information ▶
  • Define leaky gut
  • Recall basic histology/molecular biology involved in leaky gut
  • List conditions associated with leaky gut
  • Compare diagnostic tools in the differential diagnosis of leaky gut
  • Recite how the lactulose mannitol test works
  • List therapeutic interventions for leaky gut

Approved States/Territories
  • AKAlaska
  • BCBritish Columbia
  • COColorado
  • CTConnecticut
  • DEDelaware
  • DCDistrict of Columbia
  • FLFlorida
  • GUGuam
  • IDIdaho
  • ILIllinois
  • INIndiana
  • IAIowa
  • KSKansas
  • MEMaine
  • MBManitoba
  • MDMaryland
  • MAMassachusetts
  • MIMichigan
  • MNMinnesota
  • MOMissouri
  • MTMontana
  • NENebraska
  • NBNew Brunswick
  • NHNew Hampshire
  • NJNew Jersey
  • NCNorth Carolina
  • NDNorth Dakota
  • NSNova Scotia
  • OHOhio
  • ONOntario
  • OROregon
  • PRPuerto Rico
  • RIRhode Island
  • SCSouth Carolina
  • SDSouth Dakota
  • TNTennessee
  • UTUtah
  • VTVermont
  • VIVirgin Islands
  • VAVirginia
  • WAWashington
  • WVWest Virginia
  • WYWyoming
  • YTYukon

Gastroenterology 201 : Fecal Microbial Transplant Research Review
3.0

Joshua Goldenberg, ND

$60.00 USD

AudioVisual Course


More Course Information ▶
  • Summarize the current state of legal status and research on fecal microbial transplants (FMT)
  • Describe the state of research of FMT for irritable bowel syndrome
  • Describe the state of research of FMT for hepatic encephalopathy
  • Describe the state of research of FMT for antibiotic associated diarrhea/dysbiosis
  • Describe the state of research of FMT for ulcerative colitis
  • Describe the state of research of FMT for Clostridium difficile infection
  • Describe the state of research of FMT for autism



Approved States/Territories
  • AKAlaska
  • BCBritish Columbia
  • COColorado
  • CTConnecticut
  • DEDelaware
  • DCDistrict of Columbia
  • FLFlorida
  • GUGuam
  • IDIdaho
  • ILIllinois
  • INIndiana
  • IAIowa
  • KSKansas
  • MEMaine
  • MBManitoba
  • MDMaryland
  • MAMassachusetts
  • MIMichigan
  • MNMinnesota
  • MOMissouri
  • MTMontana
  • NENebraska
  • NBNew Brunswick
  • NHNew Hampshire
  • NJNew Jersey
  • NCNorth Carolina
  • NDNorth Dakota
  • NSNova Scotia
  • OHOhio
  • ONOntario
  • OROregon
  • PRPuerto Rico
  • RIRhode Island
  • SCSouth Carolina
  • SDSouth Dakota
  • TNTennessee
  • UTUtah
  • VTVermont
  • VIVirgin Islands
  • VAVirginia
  • WAWashington
  • WVWest Virginia
  • WYWyoming
  • YTYukon